OXFORD, England, September 11, 2012 /PRNewswire/ --
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann joins Circassia from GlaxoSmithKline where he was Vice President and Medicines Development Leader responsible for the late-stage development of once-daily inhaled medicines for the treatment of asthma and COPD.
"I am delighted Brett has chosen to join Circassia, where his extensive regulatory, medical and development experience will prove invaluable as we move our lead product into the final phase of clinical testing," said Steve Harris, Circassia's CEO. "With his expertise in respiratory medicine, wide network of opinion leadercontacts and proven track record in managing complex phase III studies, Brett is the ideal person to help Circassia drive its first product to market. We are confident our ToleroMune® technology has the potential to revolutionise allergy treatment, and the leadership Brett has already demonstrated in managing one of GSK's most important development programmes willhelp Circassia make thisambitious goal a reality."
Dr Brett Haumann has over 15 years' experience of pharmaceutical development gained at Glaxo Wellcome and GlaxoSmithKline. During this time, he held a number of positions of increasing seniority, culminating in his most recent role as Vice President, Medicines Development Leader where he led a multifunctional team developing GSK's next generation of inhaled respiratory